DANIEL M. MULVENA

Corporate Board Profile

Tech Score: 0/100

Yubo International Biotech Ltd

Filing Date	Source Excerpt
2001-08-08	Daniel M. Mulvena has been the Company's Chairman since March 1998 and a consultant to the Company since February 1997. Mr. Mulvena served as Chief Executive Officer of the Company from March 1998 until January 1, 2001. Mr. Mulvena devotes such time as is necessary to the business and affairs of the Company. Mr. Mulvena is Chairman of the Board of EchoCath, Inc., a publicly traded medical technology company, and serves as a consultant to and/or director of several privately-held and publicly-held medical technology companies including publicly-held Thoratec Corporation, Zoll Medical Corporation and Cambridge Heart. Mr. Mulvena is the principal owner of Commodore Associates, a private firm providing consulting services to medical technology companies. Mr. Mulvena served in various capacities at Boston Scientific Corporation, a publicly traded corporation that manufactures and sells minimally invasive medical products ("BSC"), from 1992 through 1995 including as Vice-President and General Manager and ultimately as Group Vice-President Cardio/Cardiology responsible for Mansfield, Cardiac Assist and Mansfield Electrophysiology Divisions of BSC. From 1989 through 1991, Mr. Mulvena was Chairman, President and Chief Executive Officer of, and from 1991 through 1992 was a consultant to, Lithox Systems, Inc., a developer and manufacturer of medical devices. From 1980 to 1989, Mr. Mulvena served as President of Bard Implants and Bard Cardiosurgery, all divisions of C.R. Bard, Inc. C.R. Bard, Inc. is a leading worldwide manufacturer of medical devices. Mr. Mulvena has served as Co-Chairman of the Board of Directors of Life Medical Sciences, a publicly traded corporation engaged in the research and development of technologies for use in medical applications. Directors' Compensation Beginning on January 1, 2001, the Company pays its Directors who do not receive ongoing compensation from the Company, a retainer of $10,000 in annual cash compensation (payable quarterly) for attendance at Board and committee meetings. Summary Compensation Table Daniel Mulvena, Chairman of the Board 2001 $185,000(a) -- -- (a) In addition, Mr. Mulvena was paid approximately $68,256 during the fiscal year ended February 28, 2001 for services of marketing and operations consultants retained to assist the Company with operating, regulatory and pre-market activities.

Filing Date

Source Excerpt

2001-08-08

Daniel M. Mulvena has been the Company's Chairman since March 1998 and a consultant to the Company since February 1997. Mr. Mulvena served as Chief Executive Officer of the Company from March 1998 until January 1, 2001. Mr. Mulvena devotes such time as is necessary to the business and affairs of the Company. Mr. Mulvena is Chairman of the Board of EchoCath, Inc., a publicly traded medical technology company, and serves as a consultant to and/or director of several privately-held and publicly-held medical technology companies including publicly-held Thoratec Corporation, Zoll Medical Corporation and Cambridge Heart. Mr. Mulvena is the principal owner of Commodore Associates, a private firm providing consulting services to medical technology companies. Mr. Mulvena served in various capacities at Boston Scientific Corporation, a publicly traded corporation that manufactures and sells minimally invasive medical products ("BSC"), from 1992 through 1995 including as Vice-President and General Manager and ultimately as Group Vice-President Cardio/Cardiology responsible for Mansfield, Cardiac Assist and Mansfield Electrophysiology Divisions of BSC. From 1989 through 1991, Mr. Mulvena was Chairman, President and Chief Executive Officer of, and from 1991 through 1992 was a consultant to, Lithox Systems, Inc., a developer and manufacturer of medical devices. From 1980 to 1989, Mr. Mulvena served as President of Bard Implants and Bard Cardiosurgery, all divisions of C.R. Bard, Inc. C.R. Bard, Inc. is a leading worldwide manufacturer of medical devices. Mr. Mulvena has served as Co-Chairman of the Board of Directors of Life Medical Sciences, a publicly traded corporation engaged in the research and development of technologies for use in medical applications. Directors' Compensation Beginning on January 1, 2001, the Company pays its Directors who do not receive ongoing compensation from the Company, a retainer of $10,000 in annual cash compensation (payable quarterly) for attendance at Board and committee meetings. Summary Compensation Table Daniel Mulvena, Chairman of the Board 2001 $185,000(a) -- -- (a) In addition, Mr. Mulvena was paid approximately $68,256 during the fiscal year ended February 28, 2001 for services of marketing and operations consultants retained to assist the Company with operating, regulatory and pre-market activities.

Data sourced from SEC filings. Last updated: 2026-02-03